Get the Stockscreener App
2.04
0.49%
0.01
Entero Therapeutics Inc stock is traded at $2.04, with a volume of 162.34K.
It is up +0.49% in the last 24 hours and up +37.48% over the past month.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$2.03
Open:
$2.06
24h Volume:
162.34K
Relative Volume:
0.08
Market Cap:
$3.43M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.48%
1M Performance:
+37.48%
6M Performance:
+37.85%
1Y Performance:
+74.63%
1-Day Range:
$2.0204
$2.245
1-Week Range:
$1.6501
$2.30
52-Week Range:
$0.84
$2.778
Entero Therapeutics Inc Stock (ENTO) Company Profile
Name
Entero Therapeutics Inc
Sector
Industry
Phone
561-589-7020
Address
777 YAMATO ROAD, BOCA RATON
Compare ENTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
2.04 | 3.43M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Entero Therapeutics Inc Stock (ENTO) Latest News
Is it too late to sell Entero Therapeutics Inc.Market Volume Report & AI Enhanced Trading Alerts - Newser
Trendlines Suggest Entero Therapeutics Inc. May Bottom Out SoonTrade Exit Summary & Verified High Yield Trade Plans - thegnnews.com
Price action breakdown for Entero Therapeutics Inc.July 2025 Big Picture & Smart Swing Trading Alerts - Newser
Detecting support and resistance levels for Entero Therapeutics Inc.Trade Exit Summary & Verified Entry Point Signals - Newser
Is Entero Therapeutics Inc. meeting your algorithmic filter criteriaMarket Performance Summary & Low Drawdown Trading Techniques - Newser
Applying Elliott Wave Theory to Entero Therapeutics Inc.Portfolio Risk Summary & High Win Rate Trade Tips - Newser
Entero Therapeutics Announces Reverse Stock Split - MSN
Is now a turning point for Entero Therapeutics Inc.2025 Technical Overview & Smart Investment Allocation Insights - Newser
Using portfolio simulators with Entero Therapeutics Inc. included2025 Valuation Update & Long Hold Capital Preservation Tips - Newser
News impact scoring models applied to Entero Therapeutics Inc.Weekly Profit Report & Expert Approved Momentum Trade Ideas - Newser
Long term hold vs stop loss in Entero Therapeutics Inc.Quarterly Earnings Report & Real-Time Volume Trigger Notifications - Newser
Should you wait for a breakout in Entero Therapeutics Inc.2025 Valuation Update & Trade Opportunity Analysis Reports - Newser
Combining machine learning predictions for Entero Therapeutics Inc.July 2025 Update & High Yield Stock Recommendations - Newser
Entero Therapeutics Inc. Stages Intraday Comeback — Trend Change2025 Earnings Impact & Smart Allocation Stock Tips - 선데이타임즈
Trendlines Converge — Decision Point for Entero Therapeutics Inc.July 2025 Retail & Long-Term Growth Stock Strategies - 선데이타임즈
Top Risks to Consider Before Buying Entero Therapeutics Inc. StockWeekly Loss Report & Weekly Hot Stock Watchlists - Newser
Momentum divergence signals in Entero Therapeutics Inc. chartEntry Point & High Accuracy Swing Trade Signals - Newser
Is this a good reentry point in Entero Therapeutics Inc.2025 Geopolitical Influence & Advanced Technical Analysis Signals - Newser
Entero Therapeutics Implements Reverse Stock Split to Maintain Nasdaq Listing - AInvest
Entero Therapeutics to effect 1 for 3 reverse stock split, trading on Nasdaq on August 18. - AInvest
How sentiment analysis helps forecast Entero Therapeutics Inc.July 2025 Movers & Accurate Intraday Trading Signals - Newser
What makes Entero Therapeutics Inc. stock price move sharplyEarnings Summary Report & Low Risk High Win Rate Picks - thegnnews.com
Entero Therapeutics, Inc. SEC 10-Q Report - TradingView
Entero Therapeutics stock falls after announcing reverse stock split By Investing.com - Investing.com Nigeria
Entero Therapeutics stock falls after announcing reverse stock split - Investing.com
Entero Therapeutics announces 1-for-3 reverse stock split By Investing.com - Investing.com Nigeria
Entero Therapeutics, Inc. Announces Reverse Stock Split | ENTO Stock News - GuruFocus
Entero Therapeutics announces 1-for-3 reverse stock split - Investing.com India
Entero Therapeutics Implements Reverse Stock Split to Regain Nasdaq Compliance - AInvest
Entero Therapeutics Plans 1:3 Reverse Split as Shares Drop Below Nasdaq Minimum - Stock Titan
Is Entero Therapeutics Inc. a Top Dividend Stock to Watch in 2025Earnings Risk Report & Detailed Earnings Play Strategies - Newser
Reversal Traders Monitor Entero Therapeutics Inc. for EntryM&A Rumor & Verified Momentum Stock Watchlist - beatles.ru
Entero Therapeutics Inc Stock (ENTO) Financials Data
There is no financial data for Entero Therapeutics Inc (ENTO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Entero Therapeutics Inc Stock (ENTO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Romano Sarah | Chief Financial Officer |
Oct 09 '24 |
Sale |
0.45 |
476 |
212 |
18,014 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):